Goodwin Advises the Underwriters on Silence’s $201 Million Public Offering

The Life Sciences and Capital Markets teams advised joint book-running managers Jefferies, Morgan Stanley, Cantor, and William Blair on Silence Therapeutics' public offering of 14,907,407 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the company, at a public offering price of $13.50 per ADS, inclusive of the full underwriters’ option. The gross proceeds from the offering were approximately $201 million, inclusive of the full underwriters’ option, before deducting underwriting discounts, commissions, and other offering expenses.

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. 

The Goodwin team was led by Ben Marsh, Jesse Fishman, Beth Nelson, Carrie Clowney, Sophie McGrath, Estelle Candau, Kesten Laverty, Steve Tjoe, Dan Karelitz, Dulcie Daly, Olivia Uitto, and Maggie Wong.

For more information on the deal, please read the launch press release, pricing press release, and closing press release.